MX2011002047A - Compuestos n-sulfonamido pirazolil policiclicos. - Google Patents
Compuestos n-sulfonamido pirazolil policiclicos.Info
- Publication number
- MX2011002047A MX2011002047A MX2011002047A MX2011002047A MX2011002047A MX 2011002047 A MX2011002047 A MX 2011002047A MX 2011002047 A MX2011002047 A MX 2011002047A MX 2011002047 A MX2011002047 A MX 2011002047A MX 2011002047 A MX2011002047 A MX 2011002047A
- Authority
- MX
- Mexico
- Prior art keywords
- alkyl
- sulfonyl
- phenyl
- trifluoromethyl
- pyrazole
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 198
- 208000024827 Alzheimer disease Diseases 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 19
- 208000010877 cognitive disease Diseases 0.000 claims abstract description 17
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 590
- 150000002367 halogens Chemical class 0.000 claims description 582
- -1 C0-C3alkylC02Rii Chemical group 0.000 claims description 395
- 125000003545 alkoxy group Chemical group 0.000 claims description 387
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 344
- 125000000217 alkyl group Chemical group 0.000 claims description 317
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 317
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 271
- 125000001188 haloalkyl group Chemical group 0.000 claims description 186
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 167
- 125000002252 acyl group Chemical group 0.000 claims description 167
- 125000003118 aryl group Chemical group 0.000 claims description 166
- 125000001072 heteroaryl group Chemical group 0.000 claims description 155
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 148
- 125000004076 pyridyl group Chemical group 0.000 claims description 144
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 126
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 110
- 125000005843 halogen group Chemical group 0.000 claims description 105
- 125000000335 thiazolyl group Chemical group 0.000 claims description 98
- 125000002883 imidazolyl group Chemical group 0.000 claims description 95
- 229910052801 chlorine Inorganic materials 0.000 claims description 92
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 91
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 88
- 229910052731 fluorine Inorganic materials 0.000 claims description 87
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 82
- 229910052739 hydrogen Inorganic materials 0.000 claims description 74
- 150000003839 salts Chemical class 0.000 claims description 68
- 125000004043 oxo group Chemical group O=* 0.000 claims description 67
- 229910052794 bromium Inorganic materials 0.000 claims description 65
- 125000001544 thienyl group Chemical group 0.000 claims description 65
- 229910052799 carbon Inorganic materials 0.000 claims description 63
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 61
- 125000002541 furyl group Chemical group 0.000 claims description 61
- 239000001257 hydrogen Substances 0.000 claims description 56
- 125000002971 oxazolyl group Chemical group 0.000 claims description 56
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 53
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 52
- 125000001624 naphthyl group Chemical group 0.000 claims description 48
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 47
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 47
- 229910052757 nitrogen Inorganic materials 0.000 claims description 47
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims description 46
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 46
- 125000003386 piperidinyl group Chemical group 0.000 claims description 46
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 46
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 45
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 45
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 45
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims description 44
- 125000005605 benzo group Chemical group 0.000 claims description 43
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 41
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 41
- 125000001425 triazolyl group Chemical group 0.000 claims description 40
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 39
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 38
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 37
- 125000002757 morpholinyl group Chemical group 0.000 claims description 37
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 36
- 125000001041 indolyl group Chemical group 0.000 claims description 35
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 34
- 125000005842 heteroatom Chemical group 0.000 claims description 32
- 125000000262 haloalkenyl group Chemical group 0.000 claims description 26
- 125000002632 imidazolidinyl group Chemical group 0.000 claims description 25
- 125000005055 alkyl alkoxy group Chemical group 0.000 claims description 24
- 125000002853 C1-C4 hydroxyalkyl group Chemical group 0.000 claims description 23
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 23
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 21
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 20
- 239000000203 mixture Substances 0.000 claims description 19
- 229910052717 sulfur Inorganic materials 0.000 claims description 19
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 claims description 18
- 125000003282 alkyl amino group Chemical group 0.000 claims description 17
- 125000000232 haloalkynyl group Chemical group 0.000 claims description 17
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims description 16
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims description 16
- 101150020251 NR13 gene Proteins 0.000 claims description 16
- 125000004104 aryloxy group Chemical group 0.000 claims description 16
- 125000004193 piperazinyl group Chemical group 0.000 claims description 16
- 230000004770 neurodegeneration Effects 0.000 claims description 15
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims description 14
- 125000003342 alkenyl group Chemical group 0.000 claims description 14
- 125000000304 alkynyl group Chemical group 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 12
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 12
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 12
- 206010012289 Dementia Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 11
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 125000006643 (C2-C6) haloalkenyl group Chemical group 0.000 claims description 9
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 9
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 9
- 150000001721 carbon Chemical group 0.000 claims description 8
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 8
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 7
- 201000010374 Down Syndrome Diseases 0.000 claims description 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 6
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims description 6
- 241000282414 Homo sapiens Species 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 206010002022 amyloidosis Diseases 0.000 claims description 6
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 6
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims description 5
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 5
- 125000005885 heterocycloalkylalkyl group Chemical group 0.000 claims description 5
- 230000003902 lesion Effects 0.000 claims description 5
- 208000002780 macular degeneration Diseases 0.000 claims description 5
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 4
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 4
- 230000009529 traumatic brain injury Effects 0.000 claims description 4
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 claims description 3
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 2
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 112
- VARJBHDPKQBKRJ-UHFFFAOYSA-N 5-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaene Chemical compound FC(C1=CC=C(C=N1)S(=O)(=O)N1N=CC2=C1CC1C3=C(C2N1)C=CC=C3)(F)F VARJBHDPKQBKRJ-UHFFFAOYSA-N 0.000 claims 33
- UREWVVFRSGFOEL-UHFFFAOYSA-N cyclohepta[c]pyrazole Chemical compound C1=CC=CC=C2C=NN=C21 UREWVVFRSGFOEL-UHFFFAOYSA-N 0.000 claims 23
- AJKSKJNVCGGUCC-UHFFFAOYSA-N 5-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaene Chemical compound FC(C1=CC=C(C=C1)S(=O)(=O)N1N=CC2=C1CC1C3=C(C2N1)C=CC=C3)(F)F AJKSKJNVCGGUCC-UHFFFAOYSA-N 0.000 claims 18
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 14
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims 14
- HCLXLZGAYCTHQJ-UHFFFAOYSA-N 1h-cyclohepta[b]pyridine Chemical compound C1=CC=CC=C2NC=CC=C21 HCLXLZGAYCTHQJ-UHFFFAOYSA-N 0.000 claims 12
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 12
- 230000000302 ischemic effect Effects 0.000 claims 6
- 210000004558 lewy body Anatomy 0.000 claims 6
- IKVMPQFNYJHPNV-UHFFFAOYSA-N 5-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaen-7-one Chemical compound FC(C1=CC=C(C=N1)S(=O)(=O)N1N=CC2=C1C(C1C3=C(C2N1)C=CC=C3)=O)(F)F IKVMPQFNYJHPNV-UHFFFAOYSA-N 0.000 claims 5
- GPRLUZMQXAIJFJ-UHFFFAOYSA-N (4z,6z,8z)-1h-cycloocta[c]pyrazole Chemical compound C/1=C/C=C\C=C/C2=C\1NN=C2 GPRLUZMQXAIJFJ-UHFFFAOYSA-N 0.000 claims 4
- UARAYGLXCGEMLE-UHFFFAOYSA-N 5-[6-(trifluoromethyl)pyridin-3-yl]sulfonyl-4,5,15-triazatetracyclo[6.6.1.02,6.09,14]pentadeca-2(6),3,9,11,13-pentaen-7-ol Chemical compound FC(C1=CC=C(C=N1)S(=O)(=O)N1N=CC2=C1C(C1C3=C(C2N1)C=CC=C3)O)(F)F UARAYGLXCGEMLE-UHFFFAOYSA-N 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- 208000010412 Glaucoma Diseases 0.000 claims 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 208000014674 injury Diseases 0.000 claims 4
- 201000006417 multiple sclerosis Diseases 0.000 claims 4
- 230000002207 retinal effect Effects 0.000 claims 4
- 230000008733 trauma Effects 0.000 claims 4
- CDZCREIHDRCTHZ-UHFFFAOYSA-N 2h-cyclohepta[c]pyridine Chemical compound C1=CC=CC2=CNC=CC2=C1 CDZCREIHDRCTHZ-UHFFFAOYSA-N 0.000 claims 3
- SXNMUZQWTWBSBL-UHFFFAOYSA-N 2h-cyclohepta[d][1,3]thiazole Chemical compound C1=CC=CC2=NCSC2=C1 SXNMUZQWTWBSBL-UHFFFAOYSA-N 0.000 claims 3
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims 3
- 125000006577 C1-C6 hydroxyalkyl group Chemical group 0.000 claims 2
- SJMWMJWPMICQDP-UHFFFAOYSA-N CN1N=CC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=CC(Cl)=CC=3)C2)=N1 Chemical compound CN1N=CC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=CC(Cl)=CC=3)C2)=N1 SJMWMJWPMICQDP-UHFFFAOYSA-N 0.000 claims 2
- 208000016988 Hemorrhagic Stroke Diseases 0.000 claims 2
- AXGXUPCYUWMTAD-UHFFFAOYSA-N N1=NC=C2C1=CC(=CC=C2)C#N Chemical compound N1=NC=C2C1=CC(=CC=C2)C#N AXGXUPCYUWMTAD-UHFFFAOYSA-N 0.000 claims 2
- 230000006931 brain damage Effects 0.000 claims 2
- 231100000874 brain damage Toxicity 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- SKKNGTJHVDVDQB-UHFFFAOYSA-N chembl571186 Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1C2CC(C#N)CC1CC1=C2C=NN1 SKKNGTJHVDVDQB-UHFFFAOYSA-N 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002008 hemorrhagic effect Effects 0.000 claims 2
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 2
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 1
- 125000004512 1,2,3-thiadiazol-4-yl group Chemical group S1N=NC(=C1)* 0.000 claims 1
- 125000003626 1,2,4-triazol-1-yl group Chemical group [*]N1N=C([H])N=C1[H] 0.000 claims 1
- 125000001305 1,2,4-triazol-3-yl group Chemical group [H]N1N=C([*])N=C1[H] 0.000 claims 1
- PMTLKPIKBCUVHC-UHFFFAOYSA-N 12-(4-chlorophenyl)sulfonyl-10-(1-methoxycyclopropyl)-4,5,12-triazatricyclo[6.3.1.02,6]dodeca-2(6),3-diene Chemical compound C1C(N2S(=O)(=O)C=3C=CC(Cl)=CC=3)CC=3NN=CC=3C2CC1C1(OC)CC1 PMTLKPIKBCUVHC-UHFFFAOYSA-N 0.000 claims 1
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 claims 1
- BGXCRHVOAPQTIS-UHFFFAOYSA-N C1=2C(F)=CC=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(Cl)C=C1 Chemical compound C1=2C(F)=CC=CC=2C2CC=3NN=CC=3C1N2S(=O)(=O)C1=CC=C(Cl)C=C1 BGXCRHVOAPQTIS-UHFFFAOYSA-N 0.000 claims 1
- ZPRUQFHRRGJCEQ-UHFFFAOYSA-N C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3C(COCC3)=O)CC1CC1=C2C=NN1 Chemical compound C1=CC(C(F)(F)F)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC(=CC=3)N3C(COCC3)=O)CC1CC1=C2C=NN1 ZPRUQFHRRGJCEQ-UHFFFAOYSA-N 0.000 claims 1
- FLTXKNAIPHCAGZ-UHFFFAOYSA-N C1=CC(N2)=C3C=NNC3=CC2=C1 Chemical compound C1=CC(N2)=C3C=NNC3=CC2=C1 FLTXKNAIPHCAGZ-UHFFFAOYSA-N 0.000 claims 1
- LSUKVCFBORQHPR-UHFFFAOYSA-N C1=CC(NC(=O)C)=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 Chemical compound C1=CC(NC(=O)C)=CC=C1C1CC(N2S(=O)(=O)C=3C=CC(=CC=3)C(F)(F)F)C(C=NN3)=C3CC2C1 LSUKVCFBORQHPR-UHFFFAOYSA-N 0.000 claims 1
- 229910014585 C2-Ce Inorganic materials 0.000 claims 1
- FOSIRRKMYILYLF-UHFFFAOYSA-N N1=NC=C2C1=CC=C(C=C2)O Chemical compound N1=NC=C2C1=CC=C(C=C2)O FOSIRRKMYILYLF-UHFFFAOYSA-N 0.000 claims 1
- MMKFJQJMWSBFPD-UHFFFAOYSA-N N1=NN(C)C=C1C1CC(N2S(=O)(=O)C=3C=CC(Cl)=CC=3)C(C=NN3)=C3CC2C1 Chemical compound N1=NN(C)C=C1C1CC(N2S(=O)(=O)C=3C=CC(Cl)=CC=3)C(C=NN3)=C3CC2C1 MMKFJQJMWSBFPD-UHFFFAOYSA-N 0.000 claims 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims 1
- MNFORVFSTILPAW-UHFFFAOYSA-N azetidin-2-one Chemical compound O=C1CCN1 MNFORVFSTILPAW-UHFFFAOYSA-N 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- WWBXWWWAZYGPBG-UHFFFAOYSA-N chembl1837044 Chemical compound S1C(Cl)=CC=C1S(=O)(=O)N1C2CC(C=3C=CC=CC=3)CC1CC1=C2C=NN1 WWBXWWWAZYGPBG-UHFFFAOYSA-N 0.000 claims 1
- JPQZUJGQGYTZPT-UHFFFAOYSA-N chembl1837054 Chemical compound C1=CC(Cl)=CC=C1S(=O)(=O)N1C2CC(C=3NC4=CC=CC=C4N=3)CC1CC1=C2C=NN1 JPQZUJGQGYTZPT-UHFFFAOYSA-N 0.000 claims 1
- ROCXIAVBNAMBLQ-UHFFFAOYSA-N chembl1837059 Chemical compound CC1=NOC(C2CC3C=4C=NNC=4CC(N3S(=O)(=O)C=3C=CC(Cl)=CC=3)C2)=N1 ROCXIAVBNAMBLQ-UHFFFAOYSA-N 0.000 claims 1
- SSJXIUAHEKJCMH-UHFFFAOYSA-N cyclohexane-1,2-diamine Chemical compound NC1CCCCC1N SSJXIUAHEKJCMH-UHFFFAOYSA-N 0.000 claims 1
- 201000010901 lateral sclerosis Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 description 99
- 150000002923 oximes Chemical class 0.000 description 83
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 53
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 description 35
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 24
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 23
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 description 19
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 description 19
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 description 19
- 125000004432 carbon atom Chemical group C* 0.000 description 19
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 13
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 12
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 12
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 12
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 11
- 229910052760 oxygen Inorganic materials 0.000 description 11
- 102000005650 Notch Receptors Human genes 0.000 description 10
- 108010070047 Notch Receptors Proteins 0.000 description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 125000000623 heterocyclic group Chemical group 0.000 description 10
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 9
- 150000002431 hydrogen Chemical group 0.000 description 9
- 125000001424 substituent group Chemical group 0.000 description 9
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 8
- 102100022033 Presenilin-1 Human genes 0.000 description 8
- 108010050254 Presenilins Proteins 0.000 description 8
- 229940024606 amino acid Drugs 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 125000004122 cyclic group Chemical group 0.000 description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 102000015499 Presenilins Human genes 0.000 description 7
- 125000004103 aminoalkyl group Chemical group 0.000 description 7
- 210000004556 brain Anatomy 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 208000037259 Amyloid Plaque Diseases 0.000 description 6
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 6
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 108010036933 Presenilin-1 Proteins 0.000 description 6
- 125000002947 alkylene group Chemical group 0.000 description 6
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 6
- 238000005192 partition Methods 0.000 description 6
- 229920000728 polyester Polymers 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 125000002009 alkene group Chemical group 0.000 description 5
- 125000001309 chloro group Chemical group Cl* 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 239000003540 gamma secretase inhibitor Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 4
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 4
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 4
- 101000579647 Penaeus vannamei Penaeidin-2a Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229910052740 iodine Inorganic materials 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 102000046701 nicastrin Human genes 0.000 description 4
- 108700022821 nicastrin Proteins 0.000 description 4
- 125000003367 polycyclic group Chemical group 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 3
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010059245 Angiopathy Diseases 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 108700037638 Neurogenic locus notch homolog protein 1 Proteins 0.000 description 3
- 102100023181 Neurogenic locus notch homolog protein 1 Human genes 0.000 description 3
- 102100022036 Presenilin-2 Human genes 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 101150089041 aph-1 gene Proteins 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 150000001768 cations Chemical class 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000003930 cognitive ability Effects 0.000 description 3
- 125000004367 cycloalkylaryl group Chemical group 0.000 description 3
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000003412 degenerative effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 229910052744 lithium Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 2
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- SFDGJDBLYNJMFI-UHFFFAOYSA-N 3,1-benzoxazin-4-one Chemical compound C1=CC=C2C(=O)OC=NC2=C1 SFDGJDBLYNJMFI-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000617536 Homo sapiens Presenilin-1 Proteins 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 208000027382 Mental deterioration Diseases 0.000 description 2
- 206010027374 Mental impairment Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 102400000552 Notch 1 intracellular domain Human genes 0.000 description 2
- 101800001628 Notch 1 intracellular domain Proteins 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical group N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical class N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 229910052805 deuterium Inorganic materials 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 210000001671 embryonic stem cell Anatomy 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 1
- 125000006527 (C1-C5) alkyl group Chemical group 0.000 description 1
- 125000006729 (C2-C5) alkenyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XTFIVUDBNACUBN-UHFFFAOYSA-N 1,3,5-trinitro-1,3,5-triazinane Chemical compound [O-][N+](=O)N1CN([N+]([O-])=O)CN([N+]([O-])=O)C1 XTFIVUDBNACUBN-UHFFFAOYSA-N 0.000 description 1
- 125000006083 1-bromoethyl group Chemical group 0.000 description 1
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000001462 1-pyrrolyl group Chemical group [*]N1C([H])=C([H])C([H])=C1[H] 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Chemical group C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 description 1
- YTQQIHUQLOZOJI-UHFFFAOYSA-N 2,3-dihydro-1,2-thiazole Chemical compound C1NSC=C1 YTQQIHUQLOZOJI-UHFFFAOYSA-N 0.000 description 1
- 125000004174 2-benzimidazolyl group Chemical group [H]N1C(*)=NC2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
- 125000003682 3-furyl group Chemical group O1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001397 3-pyrrolyl group Chemical group [H]N1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- CWDWFSXUQODZGW-UHFFFAOYSA-N 5-thiazolyl Chemical group [C]1=CN=CS1 CWDWFSXUQODZGW-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 102000009091 Amyloidogenic Proteins Human genes 0.000 description 1
- 108010048112 Amyloidogenic Proteins Proteins 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 102400000577 C83 Human genes 0.000 description 1
- 101800001508 C83 Proteins 0.000 description 1
- 101100240518 Caenorhabditis elegans nhr-12 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 206010018341 Gliosis Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102220517591 Methyl-CpG-binding domain protein 3-like 2B_R11C_mutation Human genes 0.000 description 1
- 208000005314 Multi-Infarct Dementia Diseases 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 108020004485 Nonsense Codon Proteins 0.000 description 1
- 102000001759 Notch1 Receptor Human genes 0.000 description 1
- 108010029755 Notch1 Receptor Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108010036908 Presenilin-2 Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 201000004810 Vascular dementia Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000000033 alkoxyamino group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 230000003281 allosteric effect Effects 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 101150031224 app gene Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 125000004350 aryl cycloalkyl group Chemical group 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000011914 asymmetric synthesis Methods 0.000 description 1
- METKIMKYRPQLGS-UHFFFAOYSA-N atenolol Chemical compound CC(C)NCC(O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-UHFFFAOYSA-N 0.000 description 1
- 125000003943 azolyl group Chemical group 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 108091007737 beta-secretases Proteins 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 210000004958 brain cell Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000004617 chromonyl group Chemical group O1C(=CC(C2=CC=CC=C12)=O)* 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 125000005992 dihydrobenzisothiazinyl group Chemical group 0.000 description 1
- 125000005993 dihydrobenzisoxazinyl group Chemical group 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 125000005879 dioxolanyl group Chemical group 0.000 description 1
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical group C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- YPFLZILYILGHIK-UHFFFAOYSA-N ethyl 3-oxo-9-azabicyclo[3.3.1]nonane-7-carboxylate Chemical compound C1C(=O)CC2CC(C(=O)OCC)CC1N2 YPFLZILYILGHIK-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 102000038383 gamma-secretases Human genes 0.000 description 1
- 108091007739 gamma-secretases Proteins 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000007387 gliosis Effects 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 125000000268 heptanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- RCCPEORTSYDPMB-UHFFFAOYSA-N hydroxy benzenecarboximidothioate Chemical compound OSC(=N)C1=CC=CC=C1 RCCPEORTSYDPMB-UHFFFAOYSA-N 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000006742 locomotor activity Effects 0.000 description 1
- 231100000863 loss of memory Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000004572 morpholin-3-yl group Chemical group N1C(COCC1)* 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000005186 naphthyloxy group Chemical group C1(=CC=CC2=CC=CC=C12)O* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 125000006574 non-aromatic ring group Chemical group 0.000 description 1
- 230000037434 nonsense mutation Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000000612 phthaloyl group Chemical group C(C=1C(C(=O)*)=CC=CC1)(=O)* 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000006722 reduction reaction Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000004192 tetrahydrofuran-2-yl group Chemical group [H]C1([H])OC([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000005329 tetralinyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000030968 tissue homeostasis Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000004953 trihalomethyl group Chemical group 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/18—Bridged systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9479908P | 2008-09-05 | 2008-09-05 | |
| US9924108P | 2008-09-23 | 2008-09-23 | |
| US17327809P | 2009-04-28 | 2009-04-28 | |
| US22653209P | 2009-07-17 | 2009-07-17 | |
| PCT/US2009/055987 WO2010028213A2 (en) | 2008-09-05 | 2009-09-04 | N-sulfonamido polycyclic pyrazolyl compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011002047A true MX2011002047A (es) | 2011-06-17 |
Family
ID=41258775
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011002047A MX2011002047A (es) | 2008-09-05 | 2009-09-04 | Compuestos n-sulfonamido pirazolil policiclicos. |
Country Status (20)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009289649B2 (en) | 2008-09-03 | 2016-05-05 | Biomarin Pharmaceutical Inc. | Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors |
| US8283358B2 (en) | 2008-09-05 | 2012-10-09 | Elan Pharmaceuticals, Inc. | N-sulfonamido polycyclic pyrazolyl compounds |
| US8957066B2 (en) | 2011-02-28 | 2015-02-17 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| US10059723B2 (en) | 2011-02-28 | 2018-08-28 | Biomarin Pharmaceutical Inc. | Histone deacetylase inhibitors |
| WO2012118782A1 (en) | 2011-02-28 | 2012-09-07 | Repligen Corporation | Histone deacetylase inhibitors |
| RU2665554C2 (ru) | 2013-03-15 | 2018-08-31 | Байомарин Фармасьютикал Инк. | Ингибиторы hdac |
| EP4084797A4 (en) * | 2020-01-03 | 2024-02-21 | Blue Oak Pharmaceuticals, Inc. | COMPOUNDS AND COMPOSITIONS FOR TREATING CNS DISEASES |
| CN111909217B (zh) * | 2020-08-20 | 2023-05-02 | 昆明贵金属研究所 | 一种双(二叔丁基-4-二甲氨基苯基膦)四溴双钯(ⅱ)化合物及其制备方法和用途 |
| CN115448892B (zh) * | 2022-09-19 | 2023-07-07 | 郑州铁路职业技术学院 | 一种苯并噻二唑杂环化合物的合成方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8727989D0 (en) * | 1987-11-30 | 1988-01-06 | Merck Sharp & Dohme | Therapeutic agents |
| EP0330788A1 (en) | 1988-03-01 | 1989-09-06 | Merrell Dow Pharmaceuticals Inc. | Use of quinolizine and quinolizinone derivatives in the manufacture of medicaments for the treatment of cardiac arrhythmia |
| WO2005113542A2 (en) | 2004-05-20 | 2005-12-01 | Elan Pharmaceuticals, Inc. | N-cyclic sulfonamido inhibitors of gamma secretase |
| JP2009504773A (ja) * | 2005-08-19 | 2009-02-05 | エラン ファーマシューティカルズ,インコーポレイテッド | ガンマセクレターゼの架橋n−二環式スルホンアミド阻害剤 |
| TW200813054A (en) | 2006-06-02 | 2008-03-16 | Elan Pharm Inc | Fused, tricyclic sulfonamide inhibitors of gamma secretase |
| CN101128035B (zh) | 2006-08-18 | 2011-08-24 | 中兴通讯股份有限公司 | 时分码分多址系统中信道间的定时方法 |
| MX2009012525A (es) * | 2007-05-25 | 2009-12-09 | Elan Pharm Inc | Pirazol-pirrolidinas como inhibidores de gamma secretasa. |
| US8283358B2 (en) | 2008-09-05 | 2012-10-09 | Elan Pharmaceuticals, Inc. | N-sulfonamido polycyclic pyrazolyl compounds |
-
2009
- 2009-09-04 US US12/554,134 patent/US8283358B2/en not_active Expired - Fee Related
- 2009-09-04 EA EA201170421A patent/EA201170421A1/ru unknown
- 2009-09-04 TW TW098129931A patent/TW201014856A/zh unknown
- 2009-09-04 AR ARP090103413A patent/AR073497A1/es not_active Application Discontinuation
- 2009-09-04 AU AU2009289579A patent/AU2009289579A1/en not_active Abandoned
- 2009-09-04 CN CN2009801426386A patent/CN102203089A/zh active Pending
- 2009-09-04 BR BRPI0918213A patent/BRPI0918213A2/pt not_active IP Right Cessation
- 2009-09-04 WO PCT/US2009/055987 patent/WO2010028213A2/en not_active Ceased
- 2009-09-04 EP EP09792258A patent/EP2346863A2/en not_active Withdrawn
- 2009-09-04 PE PE2011000438A patent/PE20110418A1/es not_active Application Discontinuation
- 2009-09-04 CA CA2736767A patent/CA2736767A1/en not_active Abandoned
- 2009-09-04 MX MX2011002047A patent/MX2011002047A/es unknown
- 2009-09-04 JP JP2011526217A patent/JP2012502051A/ja active Pending
- 2009-09-04 KR KR1020117007863A patent/KR20110055715A/ko not_active Withdrawn
-
2011
- 2011-02-17 IL IL211263A patent/IL211263A0/en unknown
- 2011-02-24 CL CL2011000405A patent/CL2011000405A1/es unknown
- 2011-03-16 ZA ZA2011/01994A patent/ZA201101994B/en unknown
- 2011-03-31 CO CO11039494A patent/CO6362008A2/es not_active Application Discontinuation
- 2011-04-01 MA MA33737A patent/MA32688B1/fr unknown
- 2011-04-01 EC EC2011010947A patent/ECSP11010947A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2346863A2 (en) | 2011-07-27 |
| IL211263A0 (en) | 2011-04-28 |
| US20100081680A1 (en) | 2010-04-01 |
| KR20110055715A (ko) | 2011-05-25 |
| EA201170421A1 (ru) | 2012-01-30 |
| ECSP11010947A (es) | 2011-07-29 |
| BRPI0918213A2 (pt) | 2015-12-08 |
| CO6362008A2 (es) | 2012-01-20 |
| AU2009289579A1 (en) | 2010-03-11 |
| AR073497A1 (es) | 2010-11-10 |
| TW201014856A (en) | 2010-04-16 |
| WO2010028213A2 (en) | 2010-03-11 |
| US8283358B2 (en) | 2012-10-09 |
| PE20110418A1 (es) | 2011-06-22 |
| ZA201101994B (en) | 2011-11-30 |
| CN102203089A (zh) | 2011-09-28 |
| CL2011000405A1 (es) | 2011-07-01 |
| MA32688B1 (fr) | 2011-10-02 |
| WO2010028213A3 (en) | 2010-06-03 |
| CA2736767A1 (en) | 2010-03-11 |
| JP2012502051A (ja) | 2012-01-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8283358B2 (en) | N-sulfonamido polycyclic pyrazolyl compounds | |
| EP2686325B1 (en) | Morpholine-spirocyclic piperidine amides as modulators of ion channels | |
| CN101501032B (zh) | 作为γ-分泌酶抑制剂的稠合的三环磺酰胺 | |
| SG192248A1 (en) | Pyrrolopyrazine-spirocyclic piperidine amides as modulators of ion channels | |
| JP7606591B2 (ja) | Mtorc1モジュレーターおよびその使用 | |
| EP2152713B1 (en) | Pyrazolopyrrolidines as inhibitors of gamma secretase | |
| RU2422443C2 (ru) | Соединенные мостиковой связью n-циклические сульфонамидо-ингибиторы гамма-секретазы | |
| CN119731156A (zh) | 依莫帕米结合蛋白抑制剂及其用途 | |
| CN119855809A (zh) | 依莫帕米结合蛋白抑制剂及其用途 | |
| HK1132270A (en) | Fused, tricyclic sulfonamide inhibitors of gamma secretase | |
| NZ615014B2 (en) | Morpholine-spirocyclic piperidine amides as modulators of ion channels |